February 24, 2025





## **APPROVE PROCEDURES**

### **CONFIDENTIAL**



Chicago, IL 60606

www.juniperadvisory.com

Jordan Shields	312.506.3005	∣ ⊠ jshields@juniperadvisory.com
Rex Burgdorfer	312.506.3006	$  \bowtie rburgdorfer@juniperadvisory.com$
Casey Webb	312.506.3010	⊠ cwebb@juniperadvisory.com
Chris Benson	3 480.855.5061	∣ ⊠ cbenson@juniperadvisory.com
Nina Leutz	224.216.9623	∣ ⊠ nleutz@juniperadvisory.com
JoJo Cerisano	312.506.3004	⊠ jcerisano@juniperadvisory.com

	Page
1 JUNIPER ADVISORY introduction	3
PROCESS OUTLINE timeline & review	6
3 PARTNERSHIP OBJECTIVES summary	13
PROCESS PARTICIPANTS	15
5 NEXT STEPS	19

This presentation was prepared exclusively for the benefit and internal use of the Juniper Advisory client to whom it is directly addressed and delivered (including such client's subsidiaries, the "Company") in order to assist the Company in evaluating, on a preliminary basis, the feasibility of a possible transaction or transactions and does not carry any right of publication or disclosure, in whole or in part, to any other party. This presentation is for discussion purposes only and is incomplete without reference to, and should be viewed solely in conjunction with, the oral briefing provided by Juniper Advisory. Neither this presentation nor any of its contents may be disclosed or used for any other purpose without the prior written consent of Juniper Advisory. The information in this presentation is based upon any management forecasts supplied to us and reflects prevailing conditions and our views as of this date, all of which are accordingly subject to change. Juniper Advisory's opinions and estimates constitute Juniper Advisory's judgment and should be regarded as indicative, preliminary and for illustrative purposes only. In preparing this presentation, we have relied upon and assumed, without independent verification, the accuracy and completeness of all information available from public sources or which was provided to us by or on behalf of the Company or which was otherwise reviewed by us. In addition, our analyses are not and do not purport to be appraisals of the assets, stock, or business of the Company or any other entity. Juniper Advisory makes no representations as to the actual value which may be received in connection with a transaction nor the legal, tax or accounting effects of consummating a transaction. Unless expressly contemplated hereby, the information in this presentation does not take into account the effects of a possible transaction or transactions involving an actual or potential change of control, which may have significant valuation and other effects. This presentation does not



# 1. JUNIPER ADVISORY

introduction

### JUNIPER ADVISORY overview

- Specialized M&A advisory firm
  - Focus exclusively on strategic M&A advisory services for nonprofit health systems
  - No conflicts of interest or cross-selling pressures
  - Independent, privately-held
  - Only experienced group with full-time, dedicated approach
- Team & experience
  - Over 30 years of hospital M&A experience
  - Creative transactions - many 'firsts'
  - Leader in formation of AMC joint ventures
  - Largest team in industry devoted solely to acute-care M&A
  - First transaction approved under new OHA requirements
- Singular focus on Board-level advisory
  - Objective advice, long term viewpoint
  - Development and implementation of processes to assess independence
  - Guidance regarding strategic range of options, including independence
- National expert on topics important to hospital Boards
  - Research publications, frequent lecturer, media resource

### By the Numbers

30-year track-record

250 assignments, 42 states

125 transactions

0 clients left without a partner

0 attorney general challenges

50+ publications

## Client profile

100% nonprofit health systems

70% client joining a system

50% 501c3


25% public hospitals

15% faith-based

10% academic


50% premium achieved to market terms & value

### **EXPERIENCE** ~250 advisory assignments, ~125 completed M&A transactions, ~45 states



- Experience with all potential partners
- Governance Inst. faculty hospital M&A
- Full knowledge of competitive environment, and suitor orientation

JUNIPER ADVISORY




## 2. PROCESS OUTLINE

timeline & review

### PRELIMINARY TIMELINE overall approach

Implementing a competitive process is central to achieving the Board's objectives and securing regulatory approval




#### Key

// = Board decision to stop or continue


Board Meetings: 2/24, 4/28, 5/19, 6/23, 8/18, 9/22, 11/17, 12/15

\* = Special Board Meeting

## **TIMELINE** preparation



### TIMELINE market input



PROCESS OUTLINE

### PROCESS OUTLINE approach

### **OBJECTIVE**

### **COMMENTS**

### ASSIST BOARD'S DECISION MAKING

- Gradual and comparative
- Do not solve for best partner now
- Receive alternative proposals
- Refine objectives during process
- Consider interplay amongst key elements
- Meet and visit suitor finalists
- Informed decision-making

# CONTROL PROCESS TIMING

- Accelerate timetable Samaritan Health Services' advantage
- Maximize negotiating leverage
- Evaluate options on a relative and absolute basis
- Avoid failures
- Minimize risk

### NEGOTIATE PRICE AND TERMS

- Various structures and forms of consideration have significant value implications
- Considerable value often associated with certain non-price matters, *e.g.*, programmatic support or expansion, commitment to services, and physicians
- Post-transaction ramifications for Samaritan Health Services should be carefully considered, *e.g.*, purchase price adjustments, indemnifications, escrows, non-competes

### MANAGE CONFIDENTIALITY

- Balance benefits of broader partner search with risk of confidentiality breach
- Protect sensitive information from competitors
- Preserve leadership focus on business
- Manage employee perceptions
- Avoid erosion of admissions by physicians
- Avoid third-party interference, e.g., state agencies, payors, competitors, unions

PROCESS OUTLINE

## PROCESS OUTLINE approach

ТҮРЕ	ADVANTAGES	DISADVANTAGES
1. BILATERAL NEGOTIATIONS private discussions conducted with one or more interested partner, provision of confidential information and negotiation of terms	<ul> <li>Discreet, can usually be kept confidential</li> <li>Simplest process</li> <li>Least disclosure</li> <li>Maximum flexibility to terminate offering without adverse consequences</li> </ul>	<ul> <li>May not receive maximum value</li> <li>Risk of choosing right partner</li> <li>Limited confidence in fairness or adequacy of value</li> <li>Lack of competition likely to force compromise on money or non-money terms</li> <li>Negotiations may be protracted and absorb senior leadership resources</li> <li>Little protection from external criticism</li> </ul>
2. SERIES OF NEGOTIATIONS one-to-one private discussions with <i>series</i> of interested partners, provision of confidential information and some negotiation of terms	<ul> <li>Fairly simple process</li> <li>Modest disclosure</li> <li>Some flexibility to terminate offering without adverse consequences</li> </ul>	<ul> <li>Difficult to compare series of offers</li> <li>Extensive commitment of senior leadership resources to protracted series of negotiations</li> <li>Extended period to complete transaction</li> <li>Difficulty in maintaining parity of treatment and evenness of information among series of interested parties</li> <li>Little protection from external criticism</li> </ul>
3. CONTROLLED COMPETITIVE PROCESS acknowledgement of intent to seek partner, followed by carefully designed and controlled program aimed at creating competitive environment	<ul> <li>Maximizes value</li> <li>Enhanced perception of process fairness, especially by external critics, e.g., AG</li> <li>Expeditious completion on timetable</li> <li>Best ability to compare offers</li> <li>Control over form of consideration and non-money terms</li> <li>Control and limitation of Board and leadership time</li> <li>Provides objectivity</li> </ul>	<ul> <li>Less discreet, generally becomes more broadly known</li> <li>Greater disclosure of information</li> <li>Some organizational uncertainty</li> <li>Less flexibility to terminate transaction without impairing future value</li> <li>Complex to manage</li> </ul>

## PROCESS OUTLINE approach

PROCESS OUTLINE

FACETS	FUNCTION
CONFIDENTIALITY AGREEMENT	<ul> <li>Augments control of confidential information</li> <li>Allows slower decision makers to drop-out before receiving confidential information</li> <li>Establish a tone of seriousness concerning handling of documents</li> <li>Enables Samaritan Health Services to withhold sensitive material until confidentiality agreement executed</li> </ul>
INFORMATION MEMORANDUM	<ul> <li>Brief description, marketing document</li> </ul>
ELECTRONIC DATA ROOM	<ul> <li>Provides detailed market, financial, and operating information sufficient for potential partners to develop preliminary view of value and other terms</li> <li>Provides sufficient information to determine interest in principle</li> </ul>
INSTRUCTION LETTERS	<ul> <li>Provides detailed description of procedures</li> <li>Allows amendments to procedures</li> <li>Specificity increases from first to second letter</li> </ul>
INITIAL AND FINAL PROPOSALS	<ul> <li>Non-binding</li> <li>Allows Samaritan Heath Services to limit number of partners with whom to negotiate</li> <li>Allows Samaritan Health Services to test market and each potential partner's interest level before facility visits and leadership interviews, or providing additional information</li> <li>Helps Board fine-tune objectives</li> </ul>
REQUEST FOR ADDITIONAL INFORMATION	<ul> <li>Controls flow of information</li> <li>Allow for systematic review of information requests</li> <li>Insulates leadership from potential partners</li> <li>Allows for the consolidation of all information requests</li> <li>Ensures uniform distribution of information</li> <li>Use of electronic data room</li> </ul>
FACILITY VISITS AND LEADERSHIP INTERVIEWS	<ul> <li>Systematic discussions between leadership and potential purchasers</li> <li>Allows system and its representatives to monitor contacts between leadership and partners</li> <li>Ensures equitable exposure to leadership and facilities by potential partners</li> </ul>
REVERSE DUE DILIGENCE	<ul> <li>Samaritan Health Services' inquiry regarding finalist suitors</li> <li>Often includes visits to suitors' hospitals</li> </ul>

 $_{\mathsf{IQ}}$  12



# 3. PARTNERSHIP OBJECTIVES


summary



### PARTNERSHIP OBJECTIVES translating feedback from key stakeholders

Based on interviews with SHS Board members, physicians, and leadership, Juniper compiled the below list of key objectives:

- Maintain Samaritan's preeminent position as the regional provider, clinical partner, and employer of choice
- Optimize Samaritan's clinical and system integration to support high value care through access to innovative resources
- Implement an efficient and effective governance structure that supports Samaritan's ability to operate fluidly and make decisions based on what is best for the community
- Expand access to needed service lines of care for all residents of the region
- Sustain a strong culture that allows Samaritan to maintain its strong operations and build on its proven ability to meet the needs of the community
- Meet Samaritan's near-term capital needs, particularly related to the Corvallis campus and health plan infrastructure



4. PROCESS PARTICIPANTS



### PROCESS PARTICIPANTS goals and approach

### **GOALS**

- Solicit interest from a group of companies that will present a range of strategic options for the board members to consider
  - Forming a sufficiently broad basis of comparison is crucial to making a sound, well-informed decision
- Satisfy internal and external stakeholders
  - Employees
  - Physicians
  - Community members
  - Competitors
  - Regulators
- Comprehensive approach to the market typically obviates need for fairness opinion
- Minimize any competitive disruption

### **APPROACH**

- Engage with a diverse mix of 35+ healthcare systems to ensure thorough outreach
  - Not-for-profit
  - Academic medical centers
  - Integrated delivery networks
  - Tax-paying & investor-owned
  - Faith-based systems
  - Public organizations
- Local, regional, and national opportunities
  - Regional synergies and national expertise
- Tailored to balance key attributes: financial stability, operational expertise, and mission alignment
- Broad, credible range of options to meet the board's objectives and inform decision-making

### **PARTNER LIST**

# System	City	State	Total Revenue (\$B)	# Hospitals# in System		EHR	Health Plan/Risk
				_=	i		-
							-
					<u>.</u>		
			-				-
					Ī		
					٠.		
			T	T			
				•			-
							-
				Ī	Ī		

Source: Definitive Healthcare, FY23-FY24 audited financial statements, FY23 10-Ks Notes:



### **PARTNER LIST**

# System	City	State	Ownership Type	Total Revenue (\$B)	# Hospitals		EHR	Health Plan/Risk
						<u> </u>		
								=
					ī	i		
								_
						i		
	_				_			=
		-						-
					Ī	i		
								-
					ī	i		=
		_				Ŀ		
								=
						i		

 ${\it Source:} \ {\it Definitive Healthcare, FY23-FY24} \ audited \ financial \ statements, FY23\ 10-Ks.$  Notes:


1. FY24 audited financial statements.

3.

2. NPR sourced from Definitive Healthcare.

4.

PROCESS PARTICIPANTS 000225 18




5. NEXT STEPS



### PRELIMINARY TIMELINE overall approach

Implementing a competitive process is central to achieving the Board's objectives and securing regulatory approval



### Key

// = Board decision to stop or continue

Board Meetings: 2/24, 4/28, 5/19, 6/23, 8/18, 9/22, 11/17, 12/15

\* = Special Board Meeting